Could adjuvant ensartinib change the treatment landscape for resected ALK-positive #NSCLC?
New phase 3 ELEVATE trial results published in NEJM highlight improved disease-free survival after surgery.
🔗 https://ow.ly/8RmT50ZvHE7
#LungCancer #Oncology
New phase 3 ELEVATE trial results published in NEJM highlight improved disease-free survival after surgery.
🔗 https://ow.ly/8RmT50ZvHE7
#LungCancer #Oncology
Postsurgical Ensartinib in ALK-Positive NSCLC
Adjuvant ensartinib may represent a new therapeutic strategy in completely resected disease.
ow.ly
August 4, 2026 at 2:05 PM
Could adjuvant ensartinib change the treatment landscape for resected ALK-positive #NSCLC?
New phase 3 ELEVATE trial results published in NEJM highlight improved disease-free survival after surgery.
🔗 https://ow.ly/8RmT50ZvHE7
#LungCancer #Oncology
New phase 3 ELEVATE trial results published in NEJM highlight improved disease-free survival after surgery.
🔗 https://ow.ly/8RmT50ZvHE7
#LungCancer #Oncology
More patients alive and cancer-free at 2 years — adjuvant ensartinib beats placebo in resected ALK+ #NSCLC 🫁
REGISTER to Get the full Newsletter 👉 buff.ly/X6N7qLU or buff.ly/4xd4naf
REGISTER to Get the full Newsletter 👉 buff.ly/X6N7qLU or buff.ly/4xd4naf
July 16, 2026 at 10:28 AM
More patients alive and cancer-free at 2 years — adjuvant ensartinib beats placebo in resected ALK+ #NSCLC 🫁
REGISTER to Get the full Newsletter 👉 buff.ly/X6N7qLU or buff.ly/4xd4naf
REGISTER to Get the full Newsletter 👉 buff.ly/X6N7qLU or buff.ly/4xd4naf
In resected 𝘈𝘓𝘒-positive non–small-cell lung cancer, treatment with ensartinib, a second-generation ALK inhibitor, led to higher disease-free survival than placebo. Learn more about the ELEVATE trial in a short Quick Take video: https://nej.md/4f3LD9u
July 11, 2026 at 10:39 PM
In resected 𝘈𝘓𝘒-positive non–small-cell lung cancer, treatment with ensartinib, a second-generation ALK inhibitor, led to higher disease-free survival than placebo. Learn more about the ELEVATE trial in a short Quick Take video: https://nej.md/4f3LD9u
Among patients with resected 𝘈𝘓𝘒-positive non–small-cell lung cancer, 2-year disease-free survival was higher with the ALK inhibitor ensartinib than with placebo. Grade 3 adverse events were more frequent with ensartinib. Full results of the ELEVATE trial: https://nej.md/4wsDQZS
July 10, 2026 at 10:44 PM
Among patients with resected 𝘈𝘓𝘒-positive non–small-cell lung cancer, 2-year disease-free survival was higher with the ALK inhibitor ensartinib than with placebo. Grade 3 adverse events were more frequent with ensartinib. Full results of the ELEVATE trial: https://nej.md/4wsDQZS
Ensartinib in Resected ALK-Positive Non–Small-Cell #LungCancer. www.nejm.org/doi/full/10....
Ensartinib in Resected ALK-Positive Non–Small-Cell Lung Cancer | NEJM
Anaplastic lymphoma kinase (ALK) inhibitors have emerged as promising agents for patients
with resectable ALK-positive non–small-cell lung cancer (NSCLC). Whether ensartinib,
a second-generation AL...
www.nejm.org
July 10, 2026 at 10:01 AM
Ensartinib in Resected ALK-Positive Non–Small-Cell #LungCancer. www.nejm.org/doi/full/10....
Ensartinib in Resected ALK-Positive Non–Small-Cell Lung Cancer
www.nejm.org/doi/full/10....
In this phase 3 trial, 274 patients with completely resected ALK-positive stage IB–IIIB #NSCLC #LungCancer received ensartinib or placebo after adjuvant chemotherapy. Ensartinib 🧪 improved DFS
www.nejm.org/doi/full/10....
In this phase 3 trial, 274 patients with completely resected ALK-positive stage IB–IIIB #NSCLC #LungCancer received ensartinib or placebo after adjuvant chemotherapy. Ensartinib 🧪 improved DFS
July 10, 2026 at 9:30 AM
Ensartinib in Resected ALK-Positive Non–Small-Cell Lung Cancer
www.nejm.org/doi/full/10....
In this phase 3 trial, 274 patients with completely resected ALK-positive stage IB–IIIB #NSCLC #LungCancer received ensartinib or placebo after adjuvant chemotherapy. Ensartinib 🧪 improved DFS
www.nejm.org/doi/full/10....
In this phase 3 trial, 274 patients with completely resected ALK-positive stage IB–IIIB #NSCLC #LungCancer received ensartinib or placebo after adjuvant chemotherapy. Ensartinib 🧪 improved DFS
Phase 3 ELEVATE data show that adjuvant ensartinib significantly improved disease-free survival vs placebo in resected ALK-positive NSCLC. @nejm.org #lcsm #oncology
www.onclive.com/view/ensarti...
www.onclive.com/view/ensarti...
Ensartinib Reduces Recurrence Risk After Resection in ALK-Positive NSCLC | OncLive
Phase 3 ELEVATE data show that adjuvant ensartinib significantly improved disease-free survival vs placebo in resected ALK-positive NSCLC.
www.onclive.com
July 9, 2026 at 3:53 PM
Phase 3 ELEVATE data show that adjuvant ensartinib significantly improved disease-free survival vs placebo in resected ALK-positive NSCLC. @nejm.org #lcsm #oncology
www.onclive.com/view/ensarti...
www.onclive.com/view/ensarti...
New in NEJM: The Phase III ELEVATE trial found that adjuvant ensartinib significantly improved disease-free survival after surgery for ALK-positive #lungcancer. Another reminder that biomarker testing is increasingly important in early-stage lung cancer too.
www.nejm.org/doi/full/10.... #LCSM
www.nejm.org/doi/full/10.... #LCSM
July 9, 2026 at 2:45 PM
New in NEJM: The Phase III ELEVATE trial found that adjuvant ensartinib significantly improved disease-free survival after surgery for ALK-positive #lungcancer. Another reminder that biomarker testing is increasingly important in early-stage lung cancer too.
www.nejm.org/doi/full/10.... #LCSM
www.nejm.org/doi/full/10.... #LCSM
New in NEJM:
Inhaled Treprostinil for Idiopathic Pulmonary Fibrosis (TETON-1 and TETON-2 trials)
Setmelanotide for Acquired Hypothalamic Obesity (TRANSCEND)
Ensartinib after Resection in ALK-Positive NSCLC (ELEVATE)
Explore the issue: https://nej.md/current-issue
Inhaled Treprostinil for Idiopathic Pulmonary Fibrosis (TETON-1 and TETON-2 trials)
Setmelanotide for Acquired Hypothalamic Obesity (TRANSCEND)
Ensartinib after Resection in ALK-Positive NSCLC (ELEVATE)
Explore the issue: https://nej.md/current-issue
July 9, 2026 at 1:00 PM
New in NEJM:
Inhaled Treprostinil for Idiopathic Pulmonary Fibrosis (TETON-1 and TETON-2 trials)
Setmelanotide for Acquired Hypothalamic Obesity (TRANSCEND)
Ensartinib after Resection in ALK-Positive NSCLC (ELEVATE)
Explore the issue: https://nej.md/current-issue
Inhaled Treprostinil for Idiopathic Pulmonary Fibrosis (TETON-1 and TETON-2 trials)
Setmelanotide for Acquired Hypothalamic Obesity (TRANSCEND)
Ensartinib after Resection in ALK-Positive NSCLC (ELEVATE)
Explore the issue: https://nej.md/current-issue
Significant Findings: Ensartinib's Role as Adjuvant Therapy for Lung Cancer Published#China#Hangzhou#Lung_Cancer#Ensartinib#Betta_Pharmaceuticals
Significant Findings: Ensartinib's Role as Adjuvant Therapy for Lung Cancer Published
A recent study published in NEJM shows that ensartinib significantly improves outcomes for ALK-positive lung cancer patients post-surgery, raising hopes for better treatment strategies.
third-news.com
July 9, 2026 at 2:26 AM
Significant Findings: Ensartinib's Role as Adjuvant Therapy for Lung Cancer Published#China#Hangzhou#Lung_Cancer#Ensartinib#Betta_Pharmaceuticals
[3/3] treatment of anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) during IBIIIB (T3N2M0) with ensartinib hydrochloride capsules (trade name: Bemena®) was published in full online in the New England Journal of Medicine.
July 9, 2026 at 12:20 AM
[3/3] treatment of anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) during IBIIIB (T3N2M0) with ensartinib hydrochloride capsules (trade name: Bemena®) was published in full online in the New England Journal of Medicine.
[1/3] 2026-07-09 08:15:44 - [Morning Announcement: The clinical research results of Betta Pharmaceuticals' ensartinib postoperative adjuvant treatment were published in the "New England Journal of Medicine"] ① Pathfinder: The application for issuance of stocks to specific objects was
July 9, 2026 at 12:20 AM
[1/3] 2026-07-09 08:15:44 - [Morning Announcement: The clinical research results of Betta Pharmaceuticals' ensartinib postoperative adjuvant treatment were published in the "New England Journal of Medicine"] ① Pathfinder: The application for issuance of stocks to specific objects was
Among patients with resected ALK-positive non–small-cell lung cancer, 2-year disease-free survival was higher with the ALK inhibitor ensartinib than with placebo. Grade 3 adverse events were more frequent with ensartinib. Full ELEVATE trial results: https://nej.md/4wsDQZS
July 8, 2026 at 10:14 PM
Among patients with resected ALK-positive non–small-cell lung cancer, 2-year disease-free survival was higher with the ALK inhibitor ensartinib than with placebo. Grade 3 adverse events were more frequent with ensartinib. Full ELEVATE trial results: https://nej.md/4wsDQZS
[2/2] and Eversana, a global commercialization service provider, have reached a cooperation to jointly promote the commercial expansion of ensacove® (ensartinib hydrochloride capsules, referred to as "ensartinib") in the U.S. market.
April 17, 2026 at 8:30 AM
[2/2] and Eversana, a global commercialization service provider, have reached a cooperation to jointly promote the commercial expansion of ensacove® (ensartinib hydrochloride capsules, referred to as "ensartinib") in the U.S. market.
[1/2] 2026-04-17 16:15:34 - [Xcovery Holdings, Inc., a subsidiary of Beida Pharmaceutical Holdings, and Eversana Company of the United States have reached a commercialization cooperation for ensartinib] Recently, Xcovery Holdings, Inc., a subsidiary of Beida Pharmaceutical Holdings,
April 17, 2026 at 8:30 AM
[1/2] 2026-04-17 16:15:34 - [Xcovery Holdings, Inc., a subsidiary of Beida Pharmaceutical Holdings, and Eversana Company of the United States have reached a commercialization cooperation for ensartinib] Recently, Xcovery Holdings, Inc., a subsidiary of Beida Pharmaceutical Holdings,
Ensartinib Hydrochloride Market Growth Drivers & Trends 2035 www.wiseguyreports.com/reports/ensa...
Ensartinib Hydrochloride Market Growth Drivers & Trends 2035
Ensartinib Hydrochloride Market Is Projected To Grow From USD 800 Billion To USD 3500 Billion by 2035, Reaching at a CAGR of 16.6% During 2025 - 2035 | Wiseguy Reports
www.wiseguyreports.com
March 10, 2026 at 12:58 PM
Ensartinib Hydrochloride Market Growth Drivers & Trends 2035 www.wiseguyreports.com/reports/ensa...
Ensartinib Hydrochloride Market Analysis (2035) www.wiseguyreports.com/reports/ensa...
Ensartinib Hydrochloride Market Analysis (2035)
The Ensartinib Hydrochloride Market Size was valued at 600 USD Million in 2024. The Ensartinib Hydrochloride Market is expected to grow from 800 USD Million in 2025 to 3,500 USD Million by 2035
www.wiseguyreports.com
February 14, 2026 at 10:35 AM
Ensartinib Hydrochloride Market Analysis (2035) www.wiseguyreports.com/reports/ensa...
This 🆕 review by Eric K Singhi & Eric S Nadler brings together long term trial data on first line ALK+ #LungCancer drugs & why early treatment choice can influence what comes next.
UK note: alectinib & lorlatinib are available here. Ensartinib is not.
link.springer.com/epdf/10.1007...
#LCSM
UK note: alectinib & lorlatinib are available here. Ensartinib is not.
link.springer.com/epdf/10.1007...
#LCSM
January 28, 2026 at 7:02 PM
This 🆕 review by Eric K Singhi & Eric S Nadler brings together long term trial data on first line ALK+ #LungCancer drugs & why early treatment choice can influence what comes next.
UK note: alectinib & lorlatinib are available here. Ensartinib is not.
link.springer.com/epdf/10.1007...
#LCSM
UK note: alectinib & lorlatinib are available here. Ensartinib is not.
link.springer.com/epdf/10.1007...
#LCSM
cabildoabierto.ar/perfil/aepiot.bsky.social
Increase Your SERP Rankings with Free Backlinks on aéPiot
#MOVED TO #DISMISS
allgraph.ro/advanced-sea...
#ENSARTINIB
headlines-world.com/advanced-sea...
blueskystarterpack.com/starter-pack...
Increase Your SERP Rankings with Free Backlinks on aéPiot
#MOVED TO #DISMISS
allgraph.ro/advanced-sea...
#ENSARTINIB
headlines-world.com/advanced-sea...
blueskystarterpack.com/starter-pack...
Cabildo Abierto
Una plataforma para discutir en serio, hecha en Argentina.
cabildoabierto.ar
December 24, 2025 at 7:19 PM
cabildoabierto.ar/perfil/aepiot.bsky.social
Increase Your SERP Rankings with Free Backlinks on aéPiot
#MOVED TO #DISMISS
allgraph.ro/advanced-sea...
#ENSARTINIB
headlines-world.com/advanced-sea...
blueskystarterpack.com/starter-pack...
Increase Your SERP Rankings with Free Backlinks on aéPiot
#MOVED TO #DISMISS
allgraph.ro/advanced-sea...
#ENSARTINIB
headlines-world.com/advanced-sea...
blueskystarterpack.com/starter-pack...
A new systematic review looks at 5 ensartinib trials in ALK+ #lungcancer.
It points to good response rates & generally tolerable side-effect profile, but the evidence is still early - most studies were open-label & we still need long-term data & comparisons with newer TKIs.
PubMed: 41148187 #LCSM
It points to good response rates & generally tolerable side-effect profile, but the evidence is still early - most studies were open-label & we still need long-term data & comparisons with newer TKIs.
PubMed: 41148187 #LCSM
November 13, 2025 at 11:04 PM
A new systematic review looks at 5 ensartinib trials in ALK+ #lungcancer.
It points to good response rates & generally tolerable side-effect profile, but the evidence is still early - most studies were open-label & we still need long-term data & comparisons with newer TKIs.
PubMed: 41148187 #LCSM
It points to good response rates & generally tolerable side-effect profile, but the evidence is still early - most studies were open-label & we still need long-term data & comparisons with newer TKIs.
PubMed: 41148187 #LCSM
Feed: "Clinical Trials Arena"
By: GlobalData Healthcare on Thursday, October 23, 2025
By: GlobalData Healthcare on Thursday, October 23, 2025
ESMO 2025: potential new adjuvant option ensartinib for ALK+ NSCLC
86.4% of patients treated with ensartinib reached 24-month disease-free survival, compared to 53.5% in the placebo control arm.
www.clinicaltrialsarena.com
October 23, 2025 at 12:51 PM
Feed: "Clinical Trials Arena"
By: GlobalData Healthcare on Thursday, October 23, 2025
By: GlobalData Healthcare on Thursday, October 23, 2025
Adjuvant ensartinib improves disease-free survival compared to placebo following complete resection of ALK-positive NSCLC, according to research presented at #ESMO25. #lcsm #ESMO2025
shorturl.at/XHWQh
shorturl.at/XHWQh
October 21, 2025 at 2:52 PM
Adjuvant ensartinib improves disease-free survival compared to placebo following complete resection of ALK-positive NSCLC, according to research presented at #ESMO25. #lcsm #ESMO2025
shorturl.at/XHWQh
shorturl.at/XHWQh
At #MLS_DC25 in Washington, a session on ALK TKIs showed how the field has moved from crizotinib in 2013 to ensartinib in 2025.
Choosing first-line therapy depends on efficacy, safety, and patient factors - there’s no one-size-fits-all in ALK+ #LungCancer
#LCSM
Choosing first-line therapy depends on efficacy, safety, and patient factors - there’s no one-size-fits-all in ALK+ #LungCancer
#LCSM
September 27, 2025 at 8:44 PM
At #MLS_DC25 in Washington, a session on ALK TKIs showed how the field has moved from crizotinib in 2013 to ensartinib in 2025.
Choosing first-line therapy depends on efficacy, safety, and patient factors - there’s no one-size-fits-all in ALK+ #LungCancer
#LCSM
Choosing first-line therapy depends on efficacy, safety, and patient factors - there’s no one-size-fits-all in ALK+ #LungCancer
#LCSM